171 related articles for article (PubMed ID: 23385635)
1. Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings.
Cigna D; D'Anna C; Zizzo C; Francofonte D; Sorrentino I; Colomba P; Albeggiani G; Armini A; Bianchi L; Bini L; Duro G
Mol Biosyst; 2013 Jun; 9(6):1162-8. PubMed ID: 23385635
[TBL] [Abstract][Full Text] [Related]
2. Differentially expressed proteins in ER+ MCF7 and ER- MDA- MB-231 human breast cancer cells by RhoGDI-α silencing and overexpression.
Hooshmand S; Ghaderi A; Yusoff K; Thilakavathy K; Rosli R; Mojtahedi Z
Asian Pac J Cancer Prev; 2014; 15(7):3311-7. PubMed ID: 24815488
[TBL] [Abstract][Full Text] [Related]
3. Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes.
Nowak A; Mechtler TP; Desnick RJ; Kasper DC
Mol Genet Metab; 2017; 120(1-2):57-61. PubMed ID: 27773586
[TBL] [Abstract][Full Text] [Related]
4. Detection of blood Gb3 deposits as a new tool for diagnosis and therapy monitoring in patients with classic Fabry disease.
Üçeyler N; Böttger J; Henkel L; Langjahr M; Mayer C; Nordbeck P; Wanner C; Sommer C
J Intern Med; 2018 Oct; 284(4):427-438. PubMed ID: 29974530
[TBL] [Abstract][Full Text] [Related]
5. Fabry disease: perspectives of urinary proteomics.
Cuccurullo M; Beneduci A; Anand S; Mignani R; Cianciaruso B; Bachi A; Capasso G
J Nephrol; 2010; 23 Suppl 16():S199-212. PubMed ID: 21170881
[TBL] [Abstract][Full Text] [Related]
6. Early markers of Fabry disease revealed by proteomics.
Matafora V; Cuccurullo M; Beneduci A; Petrazzuolo O; Simeone A; Anastasio P; Mignani R; Feriozzi S; Pisani A; Comotti C; Bachi A; Capasso G
Mol Biosyst; 2015 Jun; 11(6):1543-51. PubMed ID: 25666440
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α links heat and inflammation with Fabry pain.
Üçeyler N; Urlaub D; Mayer C; Uehlein S; Held M; Sommer C
Mol Genet Metab; 2019 Jul; 127(3):200-206. PubMed ID: 31221509
[TBL] [Abstract][Full Text] [Related]
8. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
9. The clinical potential of blood-proteomics in multiple sclerosis.
De Masi R; Pasca S; Scarpello R; Idolo A; De Donno A
BMC Neurol; 2013 May; 13():45. PubMed ID: 23692923
[TBL] [Abstract][Full Text] [Related]
10. Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.
Heo SH; Kang E; Kim YM; Go H; Kim KY; Jung JY; Kang M; Kim GH; Kim JM; Choi IH; Choi JH; Jung SC; Desnick RJ; Yoo HW; Lee BH
J Med Genet; 2017 Nov; 54(11):771-780. PubMed ID: 28835480
[TBL] [Abstract][Full Text] [Related]
11. Globotriaosylceramide-induced reduction of K
Rickert V; Kramer D; Schubert AL; Sommer C; Wischmeyer E; Üçeyler N
Exp Neurol; 2020 Feb; 324():113134. PubMed ID: 31778662
[TBL] [Abstract][Full Text] [Related]
12. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathogenesis of Central and Peripheral Nervous System Complications in Anderson-Fabry Disease.
Tuttolomondo A; Baglio I; Riolo R; Todaro F; Parrinello G; Miceli S; Simonetta I
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203231
[TBL] [Abstract][Full Text] [Related]
14. Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice.
Lakomá J; Rimondini R; Donadio V; Liguori R; Caprini M
PLoS One; 2014; 9(10):e108641. PubMed ID: 25337704
[TBL] [Abstract][Full Text] [Related]
15. Identification of proteomic signatures associated with lung cancer and COPD.
Pastor MD; Nogal A; Molina-Pinelo S; Meléndez R; Salinas A; González De la Peña M; Martín-Juan J; Corral J; García-Carbonero R; Carnero A; Paz-Ares L
J Proteomics; 2013 Aug; 89():227-37. PubMed ID: 23665002
[TBL] [Abstract][Full Text] [Related]
16. Anderson-Fabry disease: a multiorgan disease.
Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
[TBL] [Abstract][Full Text] [Related]
17. Fast fingerprinting by MALDI-TOF mass spectrometry of urinary sediment glycosphingolipids in Fabry disease.
Touboul D; Roy S; Germain DP; Baillet A; Brion F; Prognon P; Chaminade P; Laprévote O
Anal Bioanal Chem; 2005 Jul; 382(5):1209-16. PubMed ID: 15959771
[TBL] [Abstract][Full Text] [Related]
18. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla
Elsaid HOA; Rivedal M; Skandalou E; Svarstad E; Tøndel C; Birkeland E; Eikrem Ø; Babickova J; Marti HP; Furriol J
J Transl Med; 2023 Sep; 21(1):591. PubMed ID: 37670295
[TBL] [Abstract][Full Text] [Related]
19. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide.
De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
Mol Genet Metab; 2013 May; 109(1):93-9. PubMed ID: 23452955
[TBL] [Abstract][Full Text] [Related]
20. A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients.
Alharbi FJ; Geberhiwot T; Hughes DA; Ward DG
J Am Soc Mass Spectrom; 2016 Apr; 27(4):719-25. PubMed ID: 26797827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
